Healthcare Private Equity Sees Unprecedented Growth
In 2025, global healthcare private equity (PE) reached a remarkable milestone, achieving an estimated deal value of $191 billion, a substantial increase from records set in prior years. This growth was significantly influenced by the number of large deals, particularly those surpassing the $1 billion mark. While there were some slowdowns due to tariffs in the second quarter, the overall deal momentum did not falter. A record 445 buyouts were reported, indicating robust activity in the sector.
Major Contributors to Deal Value
Several factors played a vital role in this record-breaking value. Notably, the biopharma and provider segments were at the forefront, heavily driven by advancements in healthcare information technology. The medtech sector also showcased considerable growth. The combination of these factors not only fueled the rise in deal volume but also indicated a healthy rebalance, bringing investors back after recent lows.
Strong Bounce Back in Exit Values
Another highlight was the exit value, which soared to approximately $156 billion, a significant increase from the previous year's $54 billion. Analyst Kara Murphy noted that this resurgence in exit value signals a renewed interest among sponsors in privy sale processes for high-priority assets. As portfolios mature, the outlook for 2026 is expected to be vibrant, benefiting from high levels of capital ready for deployment.
Regional Performances: North America, Europe, and Asia-Pacific
Different regions showcased varying levels of enthusiasm and drive in the healthcare PE landscape. In North America, the second-quarter hurdles were largely overcome with a boost in large transactions, totaling 26 deals exceeding $1 billion in value. North America saw total exits bubble up to an anticipated $90 billion, a remarkable jump from $35 billion in 2024.
European Growth Driven by Biopharma
Over across the Atlantic, Europe marked a stellar year with a projected doubling of deal value to around $59 billion, primarily underpinned by biopharma activities. Notably, around 15 sizable deals eclipsing $1 billion further signified a thriving environment, positively impacting exit activities led by substantial transactions.
Areas of Strength Within Asia-Pacific
Meanwhile, the Asia-Pacific region reported record deal values, growing more than 30% from previous highs, with biopharma and provider segments continuing to thrive despite earlier slowdowns. Countries including Japan, India, and Australia led the charge with significant improvements in both value and transaction volume.
Growing Interest in Biopharma
Biopharma emerged as a key area of investment, with deal values climbing from $55 billion in 2024 to an impressive $80 billion in 2025. This vertical maintained a strong representation in overall deal activity, a trend that has been consistent over the past few years.
Future Trends and Opportunities to Watch
The outlook for 2026 remains optimistic as healthcare private equity continues to attract investor interest. The sustained growth in healthcare IT indicates an evolving strategy among investors focusing on robust value-creation strategies. Opportunities abound for those looking to redefine healthcare services, particularly in technology-assisted platforms.
Innovations in Physician Groups
Investor interest in physician practices is also gaining traction. Innovative approaches aimed at improving care quality while navigating traditional investment models are in demand. As investors explore these exciting avenues, they can create substantial value while enhancing healthcare delivery.
Frequently Asked Questions
What was the total deal value of healthcare private equity in 2025?
The total deal value of healthcare private equity in 2025 was estimated at $191 billion.
Which sectors contributed significantly to this growth?
The biopharma and provider segments, propelled by healthcare IT advancements, significantly contributed to this growth.
How did exit values perform in 2025 compared to previous years?
Exit values rose dramatically in 2025 to an expected $156 billion, compared to just $54 billion in 2024.
What regions saw the most significant activity in healthcare private equity?
North America, Europe, and Asia-Pacific all witnessed substantial activity, with distinct performance trends across each region.
What trends should investors watch for in healthcare PE going into 2026?
Investors should keep an eye on the growth of healthcare IT, innovations in physician groups, and the reshaping of the pharma services investment landscape.
